Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2026)

Janux Therapeutics (JANX) has reported Accumulated Expenses for 7 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 83.15% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 83.15% YoY), while the FY2025 annual figure was $4.6 million, down 60.72% from the prior year.
• Accumulated Expenses declined to $2.2 million in Q1 2026 per JANX's latest filing, from $4.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $16.0 million in Q2 2025 and bottomed at $1.4 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $5.8 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 823.47% — and 2026, when it sank 83.15%.
• Janux Therapeutics' Accumulated Expenses stood at $8.2 million in 2022, then sank by 59.62% to $3.3 million in 2023, then soared by 253.74% to $11.7 million in 2024, then sank by 60.72% to $4.6 million in 2025, then plunged by 51.02% to $2.2 million in 2026.
• Business Quant data shows JANX's Accumulated Expenses at $2.2 million in Q1 2026, $4.6 million in Q4 2025, and $4.0 million in Q3 2025.